Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction (ARTEMIS)
Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (CTOTC-12)
Sponsor: Clinical Trials in Organ Transplantation in Children
This PHASE1/PHASE2 trial investigates Liver Transplant Recipient and Living Donor (of the Respective Liver Transplant Recipient) and is currently completed. Clinical Trials in Organ Transplantation in Children leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Oct 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Oct 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Trials in Organ Transplantation in Children
- National Institute of Allergy and Infectious Diseases (NIAID)
- Rho Federal Systems Division, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .